mmahomed2Feb 1, 20191 minSeries A financingValitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversub...
mmahomed2Sep 13, 20181 minPhase I SBIR grant from the National Cancer InstituteValitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate...
mmahomed2Sep 11, 20181 minPhase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin DiseasesValitor has been awarded a Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This project will continue the ...
mmahomed2Aug 1, 20181 minValitor has recruited and hired Amy Twite, PhD Valitor has recruited and hired Amy Twite, PhD to join our team as Director Chemistry. Amy graduated from UC Berkeley’s College of Chemistry with extensive e...
mmahomed2Apr 30, 20181 minApril 30, 2018 Valitor presented the its latest preclinical data at the 2018 Association for Research in Vision and Ophthalmology conference in Honolulu, HI. This report de...
mmahomed2Apr 4, 20181 minQB3 Biotech Pitch SummitValitor was among a select group of early-stage start up companies that were invited to participate in the 2018 QB3 Biotech Pitch Summit. This was an excitin...
